Case Report Sample Work

Efficacy of intravitreal bevacizumab in the treatment of refractory central serous chorioretinopathy

The use of Intravitreal Bevacizumab, an anti-VEGF medication, for treating Refractory Central Serous Chorioretinopathy (CSCR), a condition where fluid accumulates under the retina, potentially leading to vision loss. Traditional treatment methods may not always be effective for CSCR, making it a challenging condition to treat. The document likely presents a case report detailing the use of Bevacizumab in a patient resistant to standard therapies, highlighting its potential efficacy in treating refractory CSCR.

Pubrica has done plethora of work in the area of clinical trial audits and monitoring for top pharmaceutical companies. Our CRAs will ensure a thorough review of data, frequent the sites, and perform interim analysis. All tasks in compliance to ethics committee and regulatory standards such as Schedule Y, study protocol, ICH GCP and the other regulations.

This will close in 0 seconds